Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
Type:
Grant
Filed:
May 2, 2014
Date of Patent:
August 9, 2016
Assignee:
The Regents of the University of California
Abstract: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method provides a multispecific antibody having a common light chain associated with each heteromeric polypeptide having an antibody binding domain. Additionally the method further involves introducing into the multispecific antibody a specific and complementary interaction at the interface of a first polypeptide and the interface of a second polypeptide, so as to promote heteromultimer formation and hinder homomultimer formation; and/or a free thiol-containing residue at the interface of a first polypeptide and a corresponding free thiol-containing residue in the interface of a second polypeptide, such that a non-naturally occurring disulfide bond is formed between the first and second polypeptide.
Type:
Grant
Filed:
December 27, 2013
Date of Patent:
August 9, 2016
Assignee:
Genetech, Inc.
Inventors:
W. Robert Arathoon, Paul J. Carter, Anne M. Merchant, Leonard G. Presta
Abstract: An object of the present invention to provide: a human pancreatic cancer antigen and/or a human colon cancer antigen that can be applied to the diagnosis and/or treatment of various types of cancers or tumors including pancreatic cancer and colon cancer as representative examples; a gene encoding the same; an anti-cancer vaccine using the same; or the like. The present invention provides a cancer antigen comprising a protein having the amino acid sequence shown in SEQ ID NO: 1; a peptide comprising a portion of said protein and having immune-stimulating activity; an anti-cancer vaccine comprising said peptide; a DNA having the nucleotide sequence shown in SEQ ID NO: 2, or its complementary sequence or a part or full length of these sequence; an anti-cancer vaccine comprising said DNA; and use thereof.
Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
Type:
Grant
Filed:
April 3, 2009
Date of Patent:
July 12, 2016
Assignee:
The Regents of the University of California
Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.
Type:
Grant
Filed:
February 20, 2015
Date of Patent:
July 12, 2016
Assignee:
The Regents of the University of California
Abstract: Disclosed are methods and compositions that employ FKBP-L polypeptides for modulating angiogenesis and/or tumor metastasis. The FKBP-L polypeptides may be used for the treatment of disorders mediated by angiogenesis such as cancer.
Type:
Grant
Filed:
June 8, 2007
Date of Patent:
July 5, 2016
Assignee:
ALMAC DISCOVERY LIMITED
Inventors:
Tracy Robson, Andrea Valentine, Martin Gerard O'Rourke, David Hirst
Abstract: The present disclosure relates to a diagnostic marker for breast cancer, having thioredoxin-1 as an active ingredient, and to a diagnostic kit for breast cancer using the same. The thioredoxin-1 is overexpressed in human breast cancer tissue so as to enable the early diagnosis of breast cancer or the early prediction prognosis of breast cancer, and therefore has a valuable use as a diagnostic marker for breast cancer. The present disclosure further relates to a method for the diagnosis of breast cancer comprising measuring serum thioredoxin 1 level. In addition, the method is useful in the early diagnosis of breast cancer thanks to its high diagnostic sensitivity and selectivity.
Type:
Grant
Filed:
July 27, 2012
Date of Patent:
July 5, 2016
Assignee:
PAICHAI UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
Abstract: The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.
Abstract: The present invention relates to a novel form of human EGFR found in certain tumors and conditions. The protein is termed here mLEEK, and the cDNA that encodes it has also been isolated. The mLEEK protein is capable of efficiently inducing the transcription of multiple genes resulting in various physiologic processes. Antibodies directed against the protein can be used for improving the diagnosis of diseases or for the treatment of diseases. The protein itself can be directly used or blocked for therapeutic purposes. Nucleic acid based probes or PCR primers specific for the mLEEK sequence can be used for diagnostic purposes. Inhibitory nucleic acid based molecules, such as antisense, siRNA, or shRNA, may be used for therapeutic purposes. The mLEEK sequence is essentially formed by the skipping of exons 2 through 22 in the EGF receptor gene leading to a fusion of exon 1 to exon 23. Other mutants are disclosed, which include the fusion of exon 1 to exon 24 and the fusion of exons 1 to exon 28.
Type:
Grant
Filed:
February 29, 2008
Date of Patent:
May 17, 2016
Assignee:
The Board of Trustees of the Leland Stanford Junior University
Abstract: Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.
Type:
Grant
Filed:
April 22, 2009
Date of Patent:
April 19, 2016
Assignee:
Ludwig Institute for Cancer Research Ltd.
Inventors:
Anita Grigoriadis, Otavia L. Caballero, Andrew John George Simpson
Abstract: Use of a polynucleotide encoding or a polypeptide comprising at least the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
April 12, 2016
Assignee:
METHERESIS TRANSLATIONAL RESEARCH SA
Inventors:
Paolo Maria Comoglio, Paolo Carminati, Paolo Michieli, Cristina Basilico
Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
Abstract: The invention provides the sequences of two polypeptides comprising the amino acid sequences as shown in SEQ ID NO:1 and SEQ ID NO:2, which can be used for the preparation of monoclonal antibodies against human p28GANK. The invention also provides the monoclonal antibodies against human p28GANK and their use.
Type:
Grant
Filed:
December 9, 2011
Date of Patent:
March 1, 2016
Assignee:
The Second Military Medical University, The People's Liberation Army
Inventors:
Hongyang Wang, Yao Chen, Jing Fu, Dongping Hu, Tao Luo, Liwei Dong
Abstract: The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregukted in pathologies such as cancer and to reagents and kits adapted for performing such methods. For example a correlation between VHL loss and mTOR inhibitor sensitivity in human kidney cancer cells is disclosed, indicating that VHL loss confers autonomous and angiogenic competitive advantages to such cells.
Type:
Grant
Filed:
March 17, 2006
Date of Patent:
February 16, 2016
Assignee:
The Regents of the University of California
Abstract: The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.
Type:
Grant
Filed:
September 18, 2009
Date of Patent:
January 12, 2016
Assignees:
INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, ASSISTANCE PUBLIQUE HOPITAUX DE PARIS, UNIVERSITE PARIS-EST CRETEIL VAL DE MARNE
Inventors:
Isabelle Bernard-Pierrot, Francois Radvanyi, Yves Allory, Nicolas Stransky
Abstract: A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.
Abstract: Provided herein are methods and compositions for the prognostic evaluation of a patient suspected of having, or having, cancer by assessing the expression of IMP3 in a biological sample of a patient. Methods can be used at the time of initial diagnosis of malignant tumors to identify a group of patients with a high potential to develop progression or metastasis later. Therefore, methods not only are able to provide very useful prognostic information for patients but also can help clinicians to select a candidate patient likely to benefit from early and aggressive cancer therapy. Methods and compositions for the treatment of cancer associated with expression of IMP3 are also provided.
Abstract: Materials and Methods for use in treating cell proliferative disorders related to asparagine metabolism are provided. Cell proliferative disorders include such cancers as forms of leukemia, ovarian cancers, melanomas, renal cancers, breast cancers, brain cancers, and other cancers. Methods include the use of RNA interference targeted at asparagine synthetase to enhance the efficacy of L-asparaginase therapies.
Type:
Grant
Filed:
June 2, 2011
Date of Patent:
November 10, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Philip L. Lorenzi, John N. Weinstein, Natasha J. Caplen
Abstract: This invention relates to the use of a polypeptide in the production of an immunostimulatory agent, said polypeptide comprising a sequence corresponding to the EDA domain of fibronectin, a fragment of the EDA domain which can bind to TLR4 or a variant of said EDA domain or a fragment which can bind to TLR4 and which has a homology of more than 70% with any form or natural fragment of the EDA domain. The invention also relates to the production methods and applications of said agent.
Type:
Grant
Filed:
June 13, 2006
Date of Patent:
October 13, 2015
Assignee:
PROYECTO DE BIOMEDICINA CIMA, S.L.
Inventors:
Claude Leclerc, Juan Jose Lasarte Sagastibelza, Marta Gorraiz Ayala, Jesus Prieto Valtuena
Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
Type:
Grant
Filed:
January 12, 2011
Date of Patent:
October 13, 2015
Assignee:
OncoMed Pharmaceuticals, Inc.
Inventors:
Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra, Austin L. Gurney